Searching for molecular targets in sarcoma

Biochemical Pharmacology

Volumn 84, Issue 1, 2012, Pages 1-10

  Teicher, Beverly A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ewing's sarcoma; Gene expression; Osteosarcoma liposarcoma; Rhabdomyosarcoma; Sarcoma

Indexed keywords

MICRORNA; MICRORNA 124; MICRORNA 199A2; UNCLASSIFIED DRUG;

CHONDROSARCOMA; CHROMOSOME TRANSLOCATION; EWING SARCOMA; FIBROSARCOMA; GENETIC IDENTIFICATION; HUMAN; LIPOSARCOMA; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; UPREGULATION;

EID: 84860658205     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.02.009     Document Type: Note

References (100)

1. L.E. MacConaill, P. Van Hummelen, M. Meyerson, and W.C. Hahn Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges Cancer Discov 1 2011 297 311
2. K. Tschoep, A. Kohlmann, M. Schlemmer, T. Haferlach, and R.D. Issels Gene expression profiling in sarcomas Crit Rev Oncol Hematol 63 2007 111 124
3. B.S. Taylor, J. Barretina, R.G. Maki, C.R. Antonescu, S. Singer, and M. Ladanyi Advances in sarcoma genomics and new therapeutic targets Nat Rev Cancer 11 2011 541 557
4. W.D. Tap, N. Federman, and F.C. Eilber Targeted therapies for soft-tissue sarcomas Expert Rev Anticancer Ther 7 2007 725 733
5. T.O. Nielsen, and R.B. West Translating gene expression into clinical care: sarcomas as a paradigm J Clin Oncol 28 2010 1796 1805
6. J.V.M.G. Bovee, and P.C.W. Hogendoorn Molecular pathology of sarcomas: concepts and clinical implications Virchows Arch 456 2010 193 199
7. Y. Ye, L.M. Pringle, A.W. Lau, D.N. Riquelme, H. Wang, and T. Jiang TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NFkB Oncogene 29 2010 3619 3629
8. S.L. Wolden, and K.M. Alektiar Sarcomas across the age spectrum Semin Radiat Biol 20 2010 45 51
9. R.G. Maki Pediatric sarcomas occurring in adults J Surg Oncol 97 2008 360 368
10. K. Baird, S. Davis, C.R. Antonescu, U.L. Harper, R.L. Walker, and Y. Chen Gene expression profiling of human sarcomas: insights into sarcoma biology Cancer Res 65 2005 9226 9235
11. J. Barretina, B.S. Taylor, S. Banerji, A.H. Ramos, M. Lagos-Quintana, and P.L. DeCarolis Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy Nat Genet 42 2010 715 721
12. S. Jain, R. Xu, V.G. Prieto, and P. Lee Molecular classification of soft tissue sarcomas and its clinical applications Int J Clin Exp Pathol 3 2010 416 429
13. F. Mertens, I. Panagopoulos, and N. Mandahl Genomic characteristics of soft tissue sarcomas Virchows Arch 456 2010 129 139
14. A.H. Beck, R.B. West, and M. van de Rijin Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic and predictive biomarkers Virchows Arch 456 2009 141 151
15. K.M. Skubitz, S. Pambuccian, J.C. Manivel, and A.P.N. Skubitz Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors J Trans Med 6 2008 23 35
16. J. Garcia, and A.L. Folpe The impact of advances in molecular genetics pathology on the classification, diagnosis and treatment of selected soft tissue tumors of the head and neck Head Neck Pathol 4 2010 70 76
17. L. Gibault, G. Perot, F. Chibon, S. Bonnin, P. Lagarde, and P. Terrier New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics J Pathol 223 2011 64 71
18. E. Moller, J.L. Hornick, L. Magnusson, S. Veerla, H.A. Domanski, and F. Mertens FUS-CREB3L2/L1-poisitive sarcomas show a specific gene expression profile with upregulation of CD24 and FOXL1 Clin Cancer Res 17 2011 2646 2656
19. Y. Oda, and M. Tsuneyoshi Recent advances in the molecular pathology of soft tissue sarcoma: implications for diagnosis, patient prognosis and molecular target therapy in the future Cancer Sci 100 2009 200 208
20. A.A. Jungbluth, C.R. Antonescu, K.J. Busam, K. Iversen, D. Kolb, and K. Coplan Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1or CT7 Int J Cancer 94 2001 252 256
21. P.F. Robbins, R.A. Morgan, S.A. Feldman, J.C. Yang, R.M. Sherry, and M.E. Dudley Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 J Clin Oncol 29 2011 917 924
22. M. Ladanyi, M.Y. Lui, C.R. Antonescu, A. Krause-Boehm, A. Meindl, and P. Argani The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 Oncogene 20 2001 48 57
23. S. Kenney, D.T. Vistica, L.H.k. Stockwin, S. Burkett, M.G. Hollingshead, and S.D. Borgel ASPS-1, a novel cell line manifesting key features of aveolar soft part sarcoma J Pediatr Hematol Oncol 33 2011 360 368
24. D.T. Vistica, P.M. Krosky, S. Kenney, M. Raffeld, and R.H. Shoemaker Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma J Pediatr Hematol Oncol 30 2008 46 52
25. S. Stacchiotti, E. Tamborini, R. Bertulli, C. Piovesan, A. Marrari, and C. Morosi Response to sunitinib malate (SM) in alveolar soft part sarcoma J Clin Oncol 26 Suppl. 2008 [abstr 10592]
26. E. Palassini, S. Stacchiotti, T. Negri, S. Brich, A. Marrari, and C. Morosi Sunitinib malate (SM) in alveolar soft part sarcoma (ASPS) J Clin Oncol 28 Suppl. 2010 [abstr 10014]
27. K. Gardner, I. Judson, M. Leahy, E. Barquin, M. Marotti, and B. Collins Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma J Clin Oncol 27 Suppl. 2009 [abstr 10523]
28. S. Kummar, A. Strassberger, A. Monks, S.P. Ivy, I.B. Turkbey, and P.L. Choyke An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS) J Clin Oncol 29 Suppl. 2011 [abstr 10001]
29. W.D. Tap, F.C. Eilber, C. Ginther, S.M. Dry, N. Reese, and K. Barzan-Smith Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization Genes Chromosomes Cancer 50 2011 95 112
30. R.M. Gobble, L.X. Qin, E.R. Brill, C.V. Angeles, S. Ugras, and R.B. O'Connor Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomas Cancer Res 71 2011 2697 2705
31. B.S. Taylor, P.L. DeCarolis, C.V. Angeles, F. Brenet, N. Schultz, and C.R. Antonescu Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas Cancer Discov 1 2011 587 597
32. S. Singer, N.D. Socci, G. Ambrosini, E. Sambol, P. Decarolis, and Y. Wu Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma Cancer Res 67 2007 6626 6636
33. S. Ugras, E. Brill, A. Jacobsen, M. Hafner, N.D. Socci, and P.L. DeCarolis Small RNA sequencing and functional characterization reveals microRNA-143 tumor suppressor activity in liposarcoma Cancer Res 71 2011 5659 5669
34. S.M. Willems, A. van Remoortere, R. van Zeijl, A.M. Deelder, L.A. McDonnell, and P.C.W. Hogendoom Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumor type and grade and reveals biochemical intratumor heterogeneity J Pathol 222 2010 400 409
35. A. Bleyer, R. Barr, B. Hayes-Lattin, D. Thomas, C. Ellis, and B. Anderson The distinctive biology of cancer in adolescents and young adults Nat Rev Cancer 8 2008 288 298
36. N.J. Balamuth, and R.B. Womer Ewing's sarcoma Lancet Oncol 11 2010 184 192
37. R. Windsor, S. Strauss, B. Seddon, and J. Whelan Experimental therapies in Ewing's sarcoma Expert Opin Invest Drugs 18 2009 143 159
38. B.A. Teicher Human tumor xenografts and mouse models of human tumors: rediscovering the models Exp Opin Drug Discov 4 2009 1295 1305
39. B.A. Teicher, R.G. Bagley, C. Rouleau, A. Kruger, Y. Ren, and L. Kurtzberg Characteristics of human Ewing/PNET sarcoma models Ann Saudi Med 31 2011 174 182
40. F. Chibon, P. Lagarde, S. Salas, G. Perot, V. Brouste, and F. Tirode Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to geneome complexity Nat Med 16 2010 781 787
41. R.L. Randall, S.L. Lessnick, K.B. Jones, L.G. Gou, J.E. Cummings, and L. Cannon-Albright Is there a predisposition gene for Ewing sarcoma J Oncol 2010 1 6
42. M. Bernstein, H. Kovar, M. Paulussen, R.L. Randall, A. Schuck, and L.A. Teot Ewing's sarcoma family of tumors: current management Oncologist 11 2006 503 519
43. J.L. Ordonez, D. Osuna, D. Herrero, E. de Alava, and J. Madoz-Gyrpide Advances in Ewing's sarcoma research: where are we now and what lies ahead Cancer Res 69 2009 7140 7150
44. M. Patel, J.M. Simon, M.D. Iglesia, S.B. Wu, A.W. McFadden, and J.D. Lieb Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription Genome Res 22 2012 259 270
45. P. Anderson, L. Kopp, N. Anderson, K. Cornelius, C. Herzog, and D. Hughes Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma) Expert Opin Invest Drugs 17 2008 1703 1715
46. K.A. France, J.L. Anderson, A. Park, and C.T. Denny Oncogenic fusion protein EWS/FLI1 down regulates gene expression by both transcriptional and post-transcriptional mechanisms J Biol Chem 286 2011 22750 22757
47. R. Taylor, H.J. Knowles, and N.A. Athanasou Ewing sarcoma cells express RANKL and support osteoclastogenesis J Pathol 225 2011 195 202
48. S. Ash, D. Luria, I.J. Cohen, Y. Goshen, H. Toledano, and J. Issakov Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry Clin Cancer Res 17 2011 2900 2907
49. M.M. Bui, G. Han, G. Acs, D. Reed, R.J. Gonzales, and T.L. Pasha Connexin 43 is a potential prognostic biomarker for Ewing sarcoma/primitive neuroectodermal tumor Sarcoma 2011 971050
50. H.G. Kang, J.M. Jenabi, J. Zhang, N. Keshelava, H. Shimada, and W.A. May E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase Cancer Res 67 2007 3094 3105
51. K. Kikuta, N. Tochigi, T. Shimoda, H. Yabe, H. Morioka, and Y. Toyama Nucleophosmin as a candidate prognostic biomarker of Ewing sarcoma revealed by proteomics Clin Cancer Res 15 2009 2885 2894
52. C. Mackintosh, J. Madoz-Gurpide, J.L. Ordonez, D. Osuna, and D. Herrero-Martin The molecular pathogenesis of Ewing sarcoma Cancer Biol Ther 9 2010 655 667
53. S. Romero, and A.P. Dei Tos Soft tissue tumors associated with EWSR1 translocation Virchows Arch 456 2010 219 234
54. C. Fisher Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations Virchows Arch 456 2010 153 166
55. M. Kauer, J. Ban, R. Kofler, B. Walker, S. Davis, and P. Meltzer A molecular function map of Ewing's sarcoma PLoS One 4 2009 e5415
56. T.L. Ng, M.J. O'Sullivan, C.J. Pallen, M. Hayes, P.W. Clarkson, and M. Winstanley Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV J Mol Diagn 9 2007 459 463
57. S. Hettmer, and A.J. Wagers Uncovering the origins of rhabdomyosarcoma Nat Med 16 2010 171 173
58. B.P. Rubin, K. Nishijo, H.I.H. Chen, X. Yi, D.P. Schuetze, and R. Pal Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma Cancer Cell 19 2011 177 191
59. E. Charytonowicz, C. Cordon-Cardo, I. Matushansky, and M. Ziman Aveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell Cancer Lett 279 2009 126 136
60. R. Tonelli, A. Intyre, C. Camerin, Z.S. Walters, K. Di Leo, and J. Selfe Antitumor activity of sustained N-Myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy Clin Cancer Res 18 2012
61. J.C. Potratz, D.N. Saunders, D.H. Wai, T.L. Ng, S.E. McKinney, and J.M. Carboni Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas Cancer Res 70 2010 8770 8781
62. T. Hosoyama, M.I. Aslam, J. Abraham, S.I. Prajapati, K. Nishijo, and J.E. Michalek IL-4R drives dedifferentiation, mitogenesis and metastasis in rhabdomyosarcoma Clin Cancer Res 17 2011 2757 2766
63. K. Thway, J. Selfe, E. Missiaglia, C. Fisher, and J. Shipley Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas J Clin Pathol 64 2011 587 591
64. A.B. Mohseny, K. Szuhai, S. Romeo, E. Buddingh, I. Briare-de Bruijn, and D. de Jong Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2 J Pathol 219 2009 294 305
65. H. Nagao, K. Ijiri, M. Hirotsu, Y. Ishidou, T. Yamamoto, and S. Nagano Role of GLI2 in the growth of human osteosarcoma J Pathol 224 2011 169 179
66. G. Maire, J.W. Martin, M. Yoshimoto, S. Chilton-MacNeill, M. Zielenska, and J.A. Squire Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma Cancer Lett 204 2011 138 146
67. S.A. Williams, H.L. Maecker, D.M. French, J. Liu, A. Gregg, and L.B. Silverstein USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma Cell 146 2011 918 930
68. C. Zou, J. Shen, Q. Tang, Z. Yang, J. Yin, and Z. Li Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis Cancer 119 2012
69. V.O. Lewis, M.G. Ozawa, M.T. Deavers, G. Wang, T. Shintani, and W. Arap The interleukin-11 receptor a as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models and human tumor samples Cancer Res 69 2009 1995 1999
70. M.F. Amary, K. Basci, F. Maggiani, S. Damato, D. Halai, and F. Berisha IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumors J Pathol 224 2011 334 343
71. M. Paoloni, S. Davis, S. Lana, S. Withrow, L. Sangiorgi, and P. Picci Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression BMC Genomics 10 2009 625
72. T. Niini, L. Lahti, F. Michelacci, S. Ninomiya, C.M. Hattinger, and M. Guled Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone Genes Chromosomes Cancer 50 2011 291 306
73. E. David, F. Blanchard, M.F. Heymann, G. DePinieux, F. Gouin, and F. Redini The bone niche of chrondrosarcoma: a sanctuary for drug resistance, tumor growth and also a source of new therapeutic targets Sarcoma 2011 932451
74. N. Presneau, A. Shalaby, H. Ye, N. Pillay, D. Halai, and B. Idowu Role of the transcription factor T (bachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study J Pathol 223 2011 327 335
75. A. Shalaby, N. Presneau, H. Ye, D. Halai, F. Berisha, and B. Idowu The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target J Pathol 223 2011 336 346
76. A.P. Dei Tos Unveiling the molecular pathogenesis of chordoma: a new paradigm for molecular targeting of rare cancers J Pathol 223 2011 565 566
77. C. Rouleau, R. Smale, Y.S. Fu, G. Hui, F. Wang, and E. Hutto Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling Int J Oncol 39 2011 73 89
78. T.O. Nielsen, F.D. Hsu, J.X. O'Connell, C.B. Gilks, P.H.B. Sorensen, and S. Linn Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology Am J Pathol 163 2003 1449 1456
79. Y. Suehara, N. Tochigi, D. Kubota, K. Kikuta, R. Nakayama, and K. Seki Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics J Proteomics 74 2011 829 842
80. T. Knosel, S. Heretsch, A. Altendorf-Hofmann, P. Richter, K. Katenkamp, and D. Katenkamp TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases Eur J Cancer 46 2010 1170 1176
81. A. Valkov, S.W. Sorbye, T.K. Kilvaer, T. Donnem, E. Smeland, and R.M. Bremnes The prognostic impact of TGF-β1, fascin, NF-κB and PKC-ζ expression in soft tissue sarcomas PLoS One 6 2011 e17507
82. N. Makinen, M. Mehine, J. Tolvanen, E. Kaasinen, Y. Li, and H.J. Lehtonen MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas Science 334 2011 252 255
83. S. Chiang, and E. Oliva Cytogenetic and molecular aberrations in endometrial stromal tumors Hum Pathol 42 2011 609 617
84. T. Guo, L. Zhang, N.E. Chang, S. Singer, R. Maki, and C.R. Antonescu Consistent MYC AND FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions Genes Chromosomes Cancer 50 2011 25 33
85. P. Collini, P.H.B. Sorensen, S. Patel, J.-Y. Blay, R.D. Issels, and R.G. Maki Sarcomas with spindle cell morphology Semin Oncol 36 2009 324 337
86. N.P. Young, D. Crowley, and T. Jacks Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis Cancer Res 71 2011 4040 4047
87. C.R. Antonescu The GIST paradigm: lessons for other kinase-driven cancers J Pathol 223 2011 251 261
88. L. Cao, Y. Yu, S. Bilke, R.L. Walker, L.H. Mayeenuddin, and D.O. Azorsa Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer Cancer Res 70 2010 6497 6508
89. O. Tomecu, S.J. Xia, D. Strezlecki, J.L. Bennicelli, J. Ginsberg, and B. Pawel Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression Lab Invest 84 2004 1060 1070
90. I.J. Davis, A.W. McFadden, Y. Zhang, A. Coxon, T.L. Burgess, and A.J. Wagner Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma Cancer Res 70 2010 639 645
91. C. Tognon, M. Garnett, E. Kenward, R. Kay, K. Morrison, and P.H.B. Sorensen The chimeric protein tyrosine kinase ETV6-NTRK3 require both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation Cancer Res 61 2001 8909 8916
92. C.E. Tognon, A.M. Somasiri, V.E. Evdokimova, G. Trigo, E.E. Uy, and N. Melnyk ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway Cancer Res 71 2010 1060 1070
93. E.L. McKinsey, J.K. Parrish, A.E. Irwin, B.F. Niemeyer, H.B. Kern, and D.K. Birks A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs Oncogene 30 2011 4910 4920
94. H.V. Erkizan, V.N. Uversky, and J.A. Toretsky Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma Clin Cancer Res 16 2010 4077 4083
95. N. Riggi, L. Cironi, P. Provero, M.L. Suva, J.C. Stehle, and K. Baumer Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid-liposarcoma Cancer Res 66 2006 7016 7023
96. R. Rodrigues, R. Rubio, I. Gutierrez-Aranda, G.J. Melen, C. Elosua, and J. Garcia-Castro FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells Stem Cells 29 2011 179 192
97. S.F. Lax Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium Pathology 39 2007 46 54
98. P. Rutkowski, A. Wozniak, and T. Switaj Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans Sarcoma 2011 959132
99. R. Barco, C.B. Garcia, and J.E. Eid The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1 PLoS One 4 2009 e5060
100. F. Armstrong, M.M. Duplantier, P. Trempat, C. Hieblot, L. Lamant, and E. Espinos Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells Oncogene 23 2004 6071 6082